Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The study will compared the effects of bosentan, an endothelin receptor antagonist, and nasal
continuous positive airway pressure (nCPAP), obstructive sleep apnea current reference
treatment, on diastolic blood pressure in untreated mildly hypertensive sleep apnea patients.
The hypothesis is that blocking endothelin receptors with a drug will have the same systemic
blood pressure lowering effect than nCPAP in sleep apnea patients.